Research Analysts’ Weekly Ratings Updates for vTv Therapeutics (VTVT)

vTv Therapeutics (NASDAQ: VTVT) recently received a number of ratings updates from brokerages and research firms:

• 8/11/2026 – vTv Therapeutics was downgraded by Weiss Ratings from “sell (d+)” to “sell (d-)”.
• 8/8/2026 – vTv Therapeutics was downgraded by Wall Street Zen from “buy” to “sell”.
• 8/7/2026 – vTv Therapeutics was downgraded by Zacks Research from “hold” to “strong sell”.
• 8/6/2026 – vTv Therapeutics had its price target lowered by HC Wainwright from $45.00 to $42.00. They now have a “buy” rating on the stock.
• 7/16/2026 – vTv Therapeutics had its price target raised by BTIG Research from $49.00 to $57.00. They now have a “buy” rating on the stock.
• 6/30/2026 – vTv Therapeutics is now covered by Rodman & Renshaw. They set a “buy” rating and a $67.00 price target on the stock.

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.